Log in Register
Menu
Search
Monoclonal Antibodies

Anti-EBV Latent Membrane Protein 1 [CS 1-4]

Invented by Prof Martin Rowe at University Of Birmingham
  • Datasheet
  • Reviews (0)
Print

Info

Review this reagent
Catalogue Number 151471
Applications IHC IF IP WB
Antigen/Gene or Protein Targets Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)
Reactivity Virus
Relevance EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases, including infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. LMP1 can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells.

CS 1-4 is specific for Epstein-Barr virus infected cells expressing the latent membrane protein (LMP). This antibody is four pooled monoclonal antibodies that collectively detect LMP's encoded by each of 20 geographically distinct EBV isolates.
Host Mouse
Subclass IgG1
Positive Control EBV transformed lymphoblastoid cell lines
Molecular Weight (kDa) 57-66
Myeloma Used P3X63Ag8.653
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Virology

References: 6 entries

Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.

View  

Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.

View  

Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.

View  

Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.

View  

Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.

IF

View  

Rowe et al. 1987. J Gen Virol. 68 ( Pt 6):1575-86. PMID: 2438376.

View  

Add a reference

References: 6 entries

Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.

View  

Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.

View  

Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.

View  

Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.

View  

Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.

IF

View  

Rowe et al. 1987. J Gen Virol. 68 ( Pt 6):1575-86. PMID: 2438376.

View  

Add a reference

References: 6 entries

Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.

View  

Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.

View  

Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.

View  

Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.

View  

Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.

IF

View  

Rowe et al. 1987. J Gen Virol. 68 ( Pt 6):1575-86. PMID: 2438376.

View  

Add a reference

    Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.

    Review this reagent


This reagent does not have any reviews at the moment.